secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2026-08-12T11:15:23+00:00
Accession:  0001193125-26-345733
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Q2 revenue drops to $9.8M from $63.7M; STRO-004 shows early responses
---------------------------------------------------------------------------

- Revenue $9.8M vs $63.7M in Q2 2025; cash $164.3M vs $202.6M at March 31, 2026.
- STRO-004 Phase 1: confirmed and unconfirmed partial responses in pancreatic, head/neck, NSCLC at 3-4 mg/kg; discontinuation rate 6%.
- STRO-004 PK: half-life ~7 days, DAR8 preserved, 25-50% more ADC exposure with 50% less payload vs conventional.
- STRO-006 Phase 1 start expected Q3 2026; STRO-227 IND on track for 2026.
- Astellas collaboration: $10M milestone received April 2026; second iADC program to enter clinic by end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000119312526345733/0001193125-26-345733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000119312526345733/stro-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-345733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer